Lantern Pharma Completes Patient Enrollment in Japan for Phase 2 Lung Cancer Trial
TL;DR
Lantern Pharma's accelerated Phase 2 trial enrollment in Japan positions it ahead in developing LP-300 for never-smoker NSCLC, offering a first-mover advantage in a high-prevalence market.
Lantern Pharma uses its RADR AI platform with 200 billion data points to advance drug candidates from AI insights to clinical trials in 2-3 years at $2.5 million per program.
LP-300 addresses significant unmet medical needs for never-smoker lung cancer patients, potentially improving treatment options and outcomes for this underserved population worldwide.
Lantern Pharma leverages AI to slash drug development timelines and costs, completing Japanese trial enrollment ahead of schedule for its innovative lung cancer treatment.
Found this article helpful?
Share it with your network and spread the knowledge!
Lantern Pharma, a clinical-stage biotechnology company leveraging artificial intelligence and machine learning in oncology drug development, has completed targeted patient enrollment in Japan for its ongoing Phase 2 HARMONIC clinical trial. The trial evaluates investigational drug candidate LP-300 in never-smoker non-small cell lung cancer patients, a population with significant unmet medical needs. This milestone was achieved ahead of schedule, demonstrating effective execution of the company's international expansion strategy.
According to Lantern Pharma CEO and President Panna Sharma, focusing on regions where never-smoker NSCLC has the highest prevalence has validated their approach. The company continues enrollment in Taiwan and the United States, moving closer to generating clinical data that could establish LP-300 as a treatment option. Lantern Pharma's proprietary AI platform, RADR, leverages over 200 billion oncology-focused data points and a library of 200+ advanced machine learning algorithms to accelerate drug development.
The company's approach has enabled newly developed drug programs to advance from initial AI insights to first-in-human clinical trials in 2-3 years at approximately $2.5 million per program. This represents a significant reduction in both time and cost compared to traditional drug development methods. The successful enrollment in Japan builds momentum for the ongoing clinical trial and highlights the potential of AI-driven approaches in addressing complex oncology challenges.
For more information about Lantern Pharma's developments, visit https://ibn.fm/LTRN. Additional details about biomedical communications can be found at https://www.BioMedWire.com. The platform provides specialized communications services for the biotechnology and life sciences sectors, offering access to extensive distribution networks and corporate communications solutions.
Curated from InvestorBrandNetwork (IBN)
